DOI: 10.1002/anie.201002220

Natural Product Synthesis

Total Synthesis of (−)-Virginiamycin M_2**

*Jie Wu and James S. Panek**

The virginiamycins are naturally occurring antibiotics produced by *Streptomyces*, comprised of two principle groups of compounds (types A and B; Figure 1). The realization that



Figure 1. Synercid (dalfopristin + quinupristin).

natural and synthetic derivatives of virginiamycins have displayed potent antibiotic activity against methicillin-, erythromycin-, and vancomycin-resistant *S.aureus*,[1] by inhibiting protein synthesis through synergistic binding of weak ribsome binders, has resulted in an active research area in both academia and industry.[2,3] These efforts resulted in the development of Synercid (Figure 1), a mixture of dalfopristin (type A) and quinupristin (type B), which was approved in the United States for the treatment of severe Gram-positive bacterial infections a little over a decade ago.[4] However, production of dalfopristin-like compounds by semisynthesis has been hampered by their sensitive functionalities and pH instability.[2] Herein, we report a concise and modular total synthesis of virginiamycin M_2, a typical member of virginiamycin group A compounds originally isolated by Todd and co-workers.[5]

Our strategy for the synthesis of virginiamycin M_2 is illustrated in Scheme 1, where we envisioned formation of the 23-membered macrocycle through a SmI_2-mediated intramolecular Barbier/Reformatsky-type cyclization[6] from the acyclic framework **2**. This material could be accessed by means of esterification of the homoallylic alcohol **3** and the proline intermediate **4**. The (*E*,*E*)-diene subunit **3** could be obtained through an efficient pathway; by using a titanium-mediated reductive alkyne–alkyne cross-coupling between the propargylic alcohol **5** and terminal alkyne **6a**,[7] which could be conveniently introduced through crotylation utilizing the organosilane (*S*)-**7**. This silane reagent has unique features as it establishes the C1−C2 *syn* stereochemistry while



Scheme 1. Retrosynthetic analysis of virginiamycin M_2. TBDPS = *tert*-butyldiphenylsilyl, TMS = trimethylsilyl.

simultaneously creating the C3−C5 (*E*)-unsaturated ester subunit, thereby functioning as a vinylogous aldol reagent.[8]

Construction of the terminal alkyne **6a** began with an asymmetric crotylation between (*S*)-**7** and isobutyraldehyde to directly obtain the vinylogous-aldol product **8** as a single diastereomer with 95% *ee* (Scheme 2A).[9] The organosilane (*S*)-**7** was obtained through an enantioselective carbene insertion catalyzed by Rh^{II} with the *ee* value reaching 95%.[10] The ester **8** was subjected to Weinreb's amidation with propargylamine in the presence of $AlMe_3$ to afford the amide **6a**. To achieve the C9–C13 fragment, the propargylic alcohol **5** was prepared from known aldehyde **10** (two steps from commercial 1,3-propandiol **9**)[11] using the Carreira

[*] J. Wu, Prof. Dr. J. S. Panek
Department of Chemistry and Center for Chemical Methodology and Library Development
Metcalf Center for Science and Engineering, Boston University
590 Commonwealth Avenue, Boston, MA 02215 (USA)
Fax: (+1) 617-358-2847
E-mail: panek@bu.edu
Homepage: http://people.bu.edu/panek/

[**] Financial support was obtained from NIH CA 53604. The authors are grateful to Dr. Baptiste Ronan at Sanofi-Aventis for ^{1}H NMR spectrum comparison of compound **22**, Dr. Yun Zhang at Novartis Institute (Cambridge, MA), Dr. Jason T. Lowe at the Broad Institute (Cambridge, MA) for helpful discussions, Dr. Paul Ralifo and Dr. Norman Lee at Boston University for assistance with NMR and HRMS measurements.

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/anie.201002220.



Entry	terminal alkyne **6**	internal alkyne	condition	yields		
				12	**13**	**14**
1	**6b**: R^1= Bn	**11**	e	**12a** (45%)	**13a** (19%)	**14a** (0%)
2	**6c**: R^1= Ac	**11**	e	**12b** (49%)	**13b** (39%)	**14b** (0%)
3	**6c**: R^1= Ac	**5**	f	**12c** (0%)	**13c** (0%)	**14c** (71%)
4	**6a**: R^1= H	**5**	f	**12d** (0%)	**13d** (16%)	**14d** (58%)



Scheme 2. A) Synthesis of C1–C8 fragment: a) Isobutyraldehyde, $TiCl_4$, CH_2Cl_2, −20 °C, 63 %, d.r. > 20:1, 95 % *ee*; b) $AlMe_3$, propargylamine, 87 %. B) Synthesis of C9–C13 fragment: c) $Zn(OTf)_2$, (−)-*N*-methylephedrine, propyne, Et_3N, 80 %, 95 % *ee*; d) TBSOTf, 2,6-lutidine, 96 %. C) Alkyne–alkyne reductive coupling: e) $Ti(OiPr)_3Cl$, cyclopentyl magnesium chloride, toluene, −78 °C to −30 °C; f) *n*BuLi, $Ti(OiPr)_3Cl$, cyclopentyl magnesium chloride, Et_2O, −78 °C to −30 °C. The reported yields are those for the product isolated after column chromtography. The yields reported for entry 4 are based on recovered starting material. OTf = trifluoromethanesulfonate, TBS = *tert*-butyldimethylsilyl.

protocol[12] and subsequent silylation with TBSOTf to afford the propargylic ether **11** (Scheme 2 B). Asymmetric addition using Carreira's protocol proceeded efficiently with propyne, and without evidence of self-aldol condensation of the starting aldehyde.

With the two alkyne reaction partners now available, our next objective was to assemble the conjugated diene fragment **14**. Although there were several options available for the construction of branched conjugated dienes,[13] we were interested in the use of a titanium-mediated reductive cross-coupling strategy, which would lead directly to the intermediate **14** without the requirement of generating preactivated and stereodefined olefinic coupling partners. In that regard, Micalizio and co-workers employed a related approach in the synthesis of callystatin A by using a homopropargylic ether.[7b] However, in the present case, the coupling of the propargylic ether **11** with a terminal alkyne did not afford the desired diene **14** (Scheme 2 C, entries 1 and 2); instead, only the regioisomer **12** and allene **13** were isolated. We envisioned that the in situ generated internal alkyne–titanium complex **int-1**[14] was allowed to undergo carbometallation with the terminal alkyne presumably through **int-2** and **int-3** to afford **12** and **13** respectively,[15] as functionalization of the terminal alkyne substrate generally occurred at the terminal carbon atom of the alkyne.[16] Notably, instead of forming the trisubstituted diene after hydrolysis, the corresponding allene compounds **13** were generated presumably through β elimination of the OTBS group in **int-3** (Scheme 2).[17] To overcome the influence of the propargylic ether, we planned to evaluate the directing ability of the secondary hydroxy group in **5** since there was a possibility that the proximal heteroatom (hydroxy group) would coordinate with the neighboring metal center.[18] The reactions were initiated by preforming the lithium oxide using *n*BuLi,[19] which would undergo ligand exchange with titanium[20] to produce lithium isopropoxide, and lead to the presumed metallacyclopropene intermediate **int-4**.[21] If the structure of tethered alkoxide **int-4** was retained during the C–C bond formation, it would preferentially afford the metallacyclopentadiene intermediate **int-6**, since **int-5** would encounter significant strain when forming the bridgehead alkene.[21] Although the coordination of alkoxide with titanium was expected to exhibit considerable ring strain in the bicyclic metallacyclopropene **int-4**,[21a] diene **14c** was obtained with excellent regioselectivity and good yield (entry 3), and without detection of by-products **12c** or **13c**. The terminal alkyne **6** also reacted in a regioselective manner to give the desired diol product **14d** (entry 4), which was accompanied by a small amount of allene by-product **13d**.[22]

The synthesis of the C14–C19 subunit (Scheme 3 A) commenced with hydrolysis of the oxazole ester **18**,[23] and subsequent coupling with D-proline benzyl ester hydrochloride. A subsequent Lewis acid promoted cleavage of the benzyl ester provided amide subunit **4** as a 3:1 mixture of rotamers.

In making use of the difference in the steric environment of the two secondary hydroxy groups in **14d**, the C11 hydroxy group was selectively silylated as a TBDPS ether **3**. Subsequent fragment coupling with **4** proceeded efficiently under the Yamaguchi condition[24] to yield **19** as a mixture of 1:1 rotamers (Scheme 3 B). The final stages of the synthesis began with the selective removal of the primary silyl group of **19**, and oxidation of the derived primary alcohol using IBX afforded the advanced aldehyde **2**.[3b] Treatment of the chloroaldehyde



Scheme 3. A) Synthesis of the C14—C19 subunit: a) LiOH, THF/H_2O (4:1), 95%; b) EDCI·HCl, (*R*)-NH(HCl)-Pro-OBn, Et_3N, 80%; c) BCl_3, −20°C to 0°C, 70%. B) Completion of the synthesis: d) TBDPSCl, imidazole, 0°C, 92%; e) **4**, 2,4,6-trichlorobenzoyl chloride, benzene, DIPEA, DMAP, 86%; f) CSA, CH_2Cl_2, MeOH, 0°C, 62% (85% brsm); g) IBX, DMSO, 92%; h) NaI, acetone, 95%; i) SmI_2, benzene, **2**, 40%; j) SmI_2, benzene, **20**, 42%; k) TFAA, DMSO, CH_2Cl_2, −78°C to −45°C, acetylacetone, Et_3N, −60°C to −35°C, 84%; l) HF·2pyridine, CH_2Cl_2, 70%. THF = tetrahydrofuran, EDCI = *N*-(3-dimethylaminopropyl)-*N*′-ethylcarbodiimide, DIPEA = *N*,*N*-diisopropylethylamine, DMAP = 4-dimethylaminopyridine, CSA = (±)-camphorsulfonic acid, IBX = *ortho*-iodoxybenzoic acid, DMSO = dimethyl sulfoxide, TFAA = trifuoroacetic acid.

2 with NaI in acetone provided iodide **20** in 95% yield. At this stage we were faced with the challenge of closing the 23-membered macrocycle and our initial experiments were unsuccessful. For instance, exposure of the advanced intermediate **20** to a THF solution of freshly prepared SmI_2[6c] led to a disappointing yield (approximately 10%) of the desired macrocyclic lactone **21**, with the majority identified as the reduced aldehyde and deiodinated material. The lower yield (<5%) obtained from highly dilute THF solution (0.002 M) indicated that the initially formed benzylic-like radical abstracted a hydrogen atom from THF, thus preventing the generation of the desired organosamarium intermediate.[25] The desired product was isolated in moderate yield (42%) as a 1:1 diastereomeric mixture when benzene was used as the reaction solvent. The less reactive chloromethyloxazole **2** underwent cyclization with similar yield. To the best of our knowledge, this is the first example of a SmI_2-mediated macrocyclization that uses benzene to suppress the competitive dehalogenation pathway. Subsequent oxidation of the resulting secondary alcohol using a modified TFAA/DMSO Swern procedure yielded the corresponding ketone in good yield. The addition of acetylacetone was used to help prevent further enolization of the ketone product.[26] Final removal of the C11 TBDPS ether using pyridine buffered HF gave virginiamycin M_2 in 70% yield. The spectral data and analytical data (^{1}H and ^{13}C NMR, IR, HRMS, optical rotation) were identical with the published data.[3a]

In summary, virginiamycin M_2 (**1**) has been synthesized in 19 steps with the longest linear sequence of 10 steps from silane (*S*)-**7** in a 6.0% overall yield. Notable features of our approach include the application of chiral silane (*S*)-**7** for the asymmetric synthesis of the *syn* vinylogous aldol product, use of an alkoxide-directed reductive coupling to construct the (*E*,*E*)-diene, and a SmI_2-promoted Barbier-type cyclization, which afforded the largest macrocycle (23-membered) among SmI_2 mediated macrocyclizations to date.[6]

Received: April 14, 2010
Revised: May 18, 2010
Published online: July 19, 2010

Keywords: antibiotics · macrocycles · natural products · silanes · total synthesis

[1] a) K. E. Brighty, P. R. McGuirk, *Annu. Rep. Med. Chem.* **1991**, *26*, 123; b) T. A. Mukhtar, G. D. Wright, *Chem. Rev.* **2005**, *105*, 529–542.

[2] a) B. Ronan, E. Bacqué, J. Barrière, S. Sablé, *Tetrahedron* **2003**, *59*, 2929–2937; b) B. Ronan, E. Bacqué, J. Barrière, *Tetrahedron* **2004**, *60*, 3819–3824; c) E. Bacqué, *Chimia* **2004**, *58*, 128–132; d) K. Nott, M. Paquot, S. Dufour, M. Eeman, M. Deleu, *Colloids Surf. B* **2009**, *69*, 268–275.

[3] For total synthesis of virginiamycin M_2, see a) R. H. Schlessinger, Y.-J. Li, *J. Am. Chem. Soc.* **1996**, *118*, 3301–3302; b) P. Breuilles, D. Uguen, *Tetrahedron Lett.* **1998**, *39*, 3149–3152. Formal synthesis of virginiamycin M_2, see c) M. S. Mortensen, J. S. Osbourn, G. A. O'Doherty, *Org. Lett.* **2007**, *9*, 3105–3108. For total synthesis of related type A virginiamycin natural products, see d) F. Tavares, J. P. Lawson, A. I. Meyers, *J. Am. Chem. Soc.* **1996**, *118*, 3303–3304; e) A. K. Ghosh, W. Liu, *J. Org. Chem.* **1997**, *62*, 7908–7909; f) D. A. Entwistle, S. I. Jordan, J. Montgomery, G. Pattenden, *Synthesis* **1998**, 603–612; g) C. A. Dvorak, W. D. Schmitz, D. J. Poon, D. C. Pryde, J. P. Lawson, R. A. Amos, A. I. Meyers, *Angew. Chem.* **2000**, *112*, 1730–1732; *Angew. Chem. Int. Ed.* **2000**, *39*, 1664–1666.

[4] a) J. C. Barrière, J. M. Paris, *Drugs Future* **1993**, *18*, 833; b) J. C. Barrière, D. Bouanchaud, J. F. Desnoottes, J. M. Paris, *Expert Opin. Invest. Drugs* **1994**, *3*, 115–131.

[5] G. R. Delpierre, F. W. Eastwood, G. E. Gream, D. G. I. Kingston, A. R. Lord Todd, D. H. Williams, *J. Chem. Soc. C* **1966**, 1653.

[6] a) D. J. Edmonds, D. Johnston, D. J. Procter, *Chem. Rev.* **2004**, *104*, 3371–3404; b) K. C. Nicolaou, S. P. Ellery, J. S. Chen, *Angew. Chem.* **2009**, *121*, 7276–7301; *Angew. Chem. Int. Ed.* **2009**, *48*, 7140–7165; c) J. T. Lowe, J. S. Panek; T. Hu, *J. Org. Chem.* **1997**, *62*, 4912–4913, *Org. Lett.* **2008**, *10*, 3813–3816.

[7] For selective recent examples of titanium mediated alkyne-alkyne reductive coupling, see a) H. L. Shimp, G. C. Micalizio, *Org. Lett.* **2005**, *7*, 5111–5114; b) H. A. Reichard, J. C. Rieger, G. C. Micalizio, *Angew. Chem.* **2008**, *120*, 7955–7958; *Angew. Chem. Int. Ed.* **2008**, *47*, 7837–7840.

[8] For reviews and recent examples of vinylogous aldol reaction, see a) G. Rassu, F. Zanardi, L. Battistini, G. Casiraghi, *Chem. Soc. Rev.* **2000**, *29*, 109–118; b) G. Casiraghi, F. Zanardi, G. Appendino, G. Rassu, *Chem. Rev.* **2000**, *100*, 1929–1972; c) S. E. Denmark, J. R. Heemstra, Jr., G. L. Beutner, *Angew. Chem.* **2005**, *117*, 4760–4777; *Angew. Chem. Int. Ed.* **2005**, *44*, 4682–4698; d) J. Hassfeld, M. Christmann, M. Kalesse, *Org. Lett.* **2001**, *3*, 3561–3564; e) M. Kalesse, S. Simsek, *Tetrahedron Lett.* **2009**, *50*, 3485–3488; f) S. E. Denmark, G. L. Beutner, *J. Am. Chem. Soc.* **2003**, *125*, 7800–7801; g) S.-U. Hormuth, H. Reissig, D.

Dorsch, *Angew. Chem.* **1993**, *105*, 1513 – 1514; *Angew. Chem. Int. Ed. Engl.* **1993**, *32*, 1449 – 1450.
[9] For *ee* analysis, see the Supporting Information.
[10] a) H. M. Davies, T. Hansen, J. Rutberg, P. R. Bruzinski, *Tetrahedron Lett.* **1997**, *38*, 1741 – 1744; b) J. Wu, Y. Chen, J. S. Panek, *Org. Lett.* **2010**, *12*, 2112 – 2115.
[11] A. Fürstner, M. D. B. Fenster, B. Fasching, C. Godbout, K. Radkowski, *Angew. Chem.* **2006**, *118*, 5632 – 5636; *Angew. Chem. Int. Ed.* **2006**, *45*, 5506 – 5510.
[12] D. E. Frantz, R. Fassler, E. M. Carreira, *J. Am. Chem. Soc.* **2000**, *122*, 1806 – 1807.
[13] For selected examples, see: a) J. S. Panek; T. Hu, *J. Org. Chem.* **1997**, *62*, 4912 – 4913; b) E.-I. Negishi, Z. Huang, G. Wang, S. Mohan, C. Wang, H. Hattori, *Acc. Chem. Res.* **2008**, *41*, 1474 – 1485; c) G. D. Allred, L. S. Liebeskind, *J. Am. Chem. Soc.* **1996**, *118*, 2748 – 2749.
[14] Generation of the internal metallacyclopropene **int-1** is crucial for titanium alkoxide mediated C–C bond formation; see a) O. G. Kulinkovich, A. DeMeijere, *Chem. Rev.* **2000**, *100*, 2789 – 2834; b) F. Sato, H. Urabe, S. Okamoto, *Chem. Rev.* **2000**, *100*, 2835 – 2886. Attempted generation of metallacyclopropene of terminal alkyne has been reported to be unsuccessful: c) K. Harada, H. Urabe, F. Sato, *Tetrahedron Lett.* **1995**, *36*, 3203 – 3206. Our control experiment attempting generation of titanium–acetylene complex on **6c** was not successful; see the Supporting Information.
[15] The regioselectivity observed was influenced significantly by the structure of the terminal alkyne. For additional control experiments, see the Supporting Information.
[16] T. Hamada, D. Suzuki, H. Urabe, F. Sato, *J. Am. Chem. Soc.* **1999**, *121*, 7342 – 7344. C–C formation at C2 of the terminal alkyne would afforded more strained transition intermediate.
[17] Allene product generation was also observed in the titanium-mediated reductive coupling of propargylic ethers and carbonyl compounds; see a) K. Yamashita, F. Sato, *Tetrahedron Lett.* **1996**, *37*, 7275 – 7278; b) T. Nakagawa, A. Kasatkin, F. Sato, *Tetrahedron Lett.* **1995**, *36*, 3207 – 3210.
[18] For recent reviews of alkoxide-directed reductive coupling, see H. A. Reichard, M. McLaughlin, M. Z. Chen, G. C. Micalizio, *Eur. J. Org. Chem.* **2010**, 391 – 409.
[19] Control experiments were carried out to test the effect of *n*BuLi; see the Supporting Information.
[20] Titanium alkoxide undergoes rapid and reversible ligand exchange; see a) K. B. Sharpless, S. S. Woodard, M. G. Finn, *Pure Appl. Chem.* **1983**, *55*, 1823 – 1836; b) S. S. Woodard, M. G. Finn, K. B. Sharpless, *J. Am. Chem. Soc.* **1991**, *113*, 106 – 113.
[21] For the possibility of generating metallacyclopropene intermediate, see a) L. J. Perez, H. L. Shimp, G. C. Micalizio, *J. Org. Chem.* **2009**, *74*, 7211 – 7219. The possibility to generate other metallacycles should not be excluded; see b) A. B. Bahadoor, G. C. Micalizio, *Org. Lett.* **2006**, *8*, 1181 – 1184.
[22] To clarify the role of functional groups and illustrate the generality of alkyne–alkyne reductive coupling using propagylic alcohol, more substrates were tested; see the Supporting Information.
[23] S. A. Hermitage, K. S. Cardwell, T. Chapman, J. W. B. Cooke, R. Newton, *Org. Process Res. Dev.* **2001**, *5*, 37 – 44.
[24] a) J. Inanaga, K. Hirata, H. Saeki, T. Katsuki, M. Yamaguchi, *Bull. Chem. Soc. Jpn*, **1979**, 52, 1989 – 1993; b) D. Ma, B. Zou, G. Cai, X. Hu, J. O. Liu, *Chem. Eur. J.* **2006**, *12*, 7615 – 7626.
[25] M. Kunishima, S. Tanaka, K. Kono, K. Hioki, S. Tani, *Tetrahedron Lett.* **1995**, *36*, 3707.
[26] D. R. Williams, A. A. Kiryanov, U. Emde, M. P. Clark, M. A. Berliner, J. T. Reeves, *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 12058 – 12063.

